IL-36γ Sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with crohn's disease

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 1891-1901

  Friedrich, Matthias ^a,b   Tillack, Cornelia ^a   Wollenberg, Andreas ^b   Schauber, Jürgen ^b   Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti TNF induced; Crohn's disease; IL 17C; IL 22; IL 23; IL 36; Inflammatory bowel disease; Psoriasiform skin lesions; Psoriasis; Th17

Indexed keywords

ALPHA INTERFERON; CD3 ANTIGEN; CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17C; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 36GAMMA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; AUTACOID; IL36G PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MESSENGER RNA; MONOCLONAL ANTIBODY;

ANTI TUMOR NECROSIS FACTOR INDUCED PSORIASIFORM SKIN LESION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DENSITOMETRY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE EXPRESSION; GUTTATE PSORIASIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; KERATINOCYTE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; STEROID THERAPY; TH17 CELL; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SKIN;

ANTIBODIES, MONOCLONAL, HUMANIZED; CELLS, CULTURED; COHORT STUDIES; CROHN DISEASE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKINS; KERATINOCYTES; PSORIASIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925650548     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000198     Document Type: Article

References (40)

1. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567-577.
2. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-1055.
3. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100-108.
4. Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318-1327.
5. Shmidt E, Wetter DA, Ferguson SB, et al. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67: e179-e185.
6. Iborra M, Beltran B, Bastida G, et al. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis. 2011;5:157-161.
7. Guerra I, Algaba A, Perez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6:518-523.
8. Buisson A, Cuny JF, Barbaud A, et al. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:1175-1180.
9. Fiorino G, Danese S, Pariente B, et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev. 2014;13:15-19.
10. Fiorino G, Allez M, Malesci A, et al. Review article: anti-TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921-927.
11. Niess JH, Danese S. Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology? Gut. 2014;63:533-535.
12. Torres J, Buche S, Delaporte E, et al. Skin side effects of inflammatory bowel disease therapy. Inflamm Bowel Dis. 2013;19:1086-1098.
13. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005;102: 3372-3377.
14. Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181:4733-4741.
15. Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118:597-607.
16. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36: 1309-1323.
17. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573-3585.
18. Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131:2428-2437.
19. Johnston A, Xing X, Guzman AM, et al. IL-1F5,-F6,-F8, and-F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186:2613-2622.
20. Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 2012;122:3965-3976.
21. Towne JE, Sims JE. IL-36 in psoriasis. Curr Opin Pharmacol. 2012;12: 486-490.
22. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17-26.
23. Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190: 2252-2262.
24. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319-324.
25. Johansen C, Riis JL, Gedebjerg A, et al. Tumor necrosis factor alphamediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor kappaB. J Biol Chem. 2011;286:25487-25494.
26. Lilleholt LL, Johansen C, Arthur JS, et al. Role of p38 mitogen-activated protein kinase isoforms in murine skin inflammation induced by 12-Otetradecanoylphorbol 13-acetate. Acta Derm Venereol. 2011;91:271-278.
27. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12:1159-1166.
28. Chang SH, Reynolds JM, Pappu BP, et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35:611-621.
29. Song X, Zhu S, Shi P, et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol. 2011;12:1151-1158.
30. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223-231.
31. Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol. 2009;161:1081-1088.
32. Schroepf S, Kappler R, Brand S, et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1882-1890.
33. Friedrich M, Diegelmann J, Beigel F, et al. IL-17A alone weakly affects the transcriptome of intestinal epithelial cells but strongly modulates the TNF-a-induced expression of inflammatory mediators and inflammatory bowel disease susceptibility genes. Inflamm Bowel Dis. 2012;20:1502-1515.
34. Seiderer J, Elben I, Diegelmann J, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008;14:437-445.
35. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 2006; 290:G827-G838.
36. Dambacher J, Beigel F, Zitzmann K, et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2009;58:1207-1217.
37. Brand S, Olszak T, Beigel F, et al. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem. 2006;97:709-723.
38. Brand S. Crohn's disease: Th1, Th17 or both? the change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58:1152-1167.
39. Schmechel S, Konrad A, Diegelmann J, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis. 2008;14:204-212.
40. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.